Floatz logo

Ipilimumab

Pediatric Solid Tumor

Dana-Farber Cancer Institutemonoclonal_antibodyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Pediatric Solid Tumor cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Robbie Majzner
Phase 1/2CCC
Carboplatin
The Korean Society of Pediatric Hematology Oncology
Phase 2CCC
Pegteograstim
Samsung Medical Center
Phase 2CCC
(+)-VINCRISTINE
St. Jude Children's Research Hospital
Phase 1/2CCC
Irinotecan
St. Jude Children's Research Hospital
Phase 1/2CCC

View all 26 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →